Cambridge UK, 30 June 2009 Orthomimetics, the Cambridge-based developer of products for regenerative medicine, has appointed Patrick West, former Global Vice President of Sales and Marketing at Stryker Biotech, to its Board of Directors.
During an eight-year tenure as Global VP of Sales and Marketing for Stryker Biotech, Patrick was responsible for the development and management of a global sales force for Stryker’s first-in-class bone morphogenetic protein product. Prior to this appointment, he had been an award-winning sales representative for Stryker’s Endoscopy division, and held responsibility for the development and market expansion activities in the Instruments division. Subsequent to his experience with Stryker, Patrick founded and served as CEO of MaxTorque LLC, a company operating in the oil and gas space. Under Patrick’s guidance, MaxTorque achieved industry-leading revenue and profit growth that culminated in the recent acquisition of the company by a strategic partner.
Commenting on the appointment, Andrew Lynn, CEO of Orthomimetics said: “Patrick brings a unique combination of large orthopaedic company and successful entrepreneurial experience to the table. This is particularly important as we turn our focus to the controlled launch of our flagship product, Chondromimetic and consider global commercial opportunities. Patrick has already made a significant contribution to Orthomimetics through his work as a Senior Commercial Advisor and we are very pleased to deepen this relationship by welcoming him to the Board.”
With regulatory approval for Chondromimetic received for Europe in December 2008, a clinical development program already underway and negotiations for European distribution in progress, OM is now looking to build its commercial links with markets worldwide.
Orthomimetics Limited is a medical technology company specialising in the design, development and manufacture of regenerative medical implants and minimally invasive delivery systems for the treatment of sports injuries, trauma and other conditions that affect knees, ankles and other articular joints. Formed in 2005 as the first spin-out venture from the Cambridge-MIT Institute, the company is bringing to market a line of medical device products designed to improve the treatment outcome of first-line surgical procedures for the regenerative repair of articular cartilage, meniscus, ligament and tendon injuries using natural biomaterials. These products are engineered to be compatible with existing surgical techniques and to work in combination with emerging cell- and biologics-based products.
For further information on Orthomimetics please go to our website: www.orthomimetics.com or contact Katherine Webster: info@orthomimetics.com
